Cancer and diabetes generic treatments receive positive opinion from EMA’s CHMP

Generics/News | Posted 25/03/2022 post-comment0 Post your comment

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 28 January 2022 that three generic medicines had received a positive opinion from the committee.

83 MD002439

The three generic medicines are: dasatinib Accord (dasatinib) and dasatinib Accord Pharma (dasatinib) for the treatment of leukaemia, and vildagliptin/metformin hydrochloride Accord (vildagliptin/metformin hydrochloride) for the treatment of type 2 diabetes. The dasatinib originator is Sprycel produced by Bristol-Myers Squibb whereas the vildagliptin/metformin hydrochloride originator is made by Novartis and has a variety of brand names including eucreas, icandra and zomarist [1].

The three generic medicines are all produced by India-based generics maker Accord Healthcare (a subsidiary of Intas Pharmaceuticals). Accord’s teriparatide biosimilar Sondelbay, also received a positive opinion from the committee in the announcement [2].

Related articles
EMA recommends approval of abiraterone and ioflupane (123I) generics

EMA recommends approval of fourth COVID-19 vaccine


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Nomenclatura de biológicos y biocomparables en México

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Nomenclatura de biológicos y biocomparables en México

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Generics applications under review by EMA January 2022 []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Mar 25]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of teriparatide and pegfilgrastim biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Mar 25]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010